Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) reported updated Phase 1/2 clinical trial data for its antibody drug conjugate CRB-701, showing ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA